Why did EW stock rise after the earnings release?

The stock rose due to the earnings and revenue beat, as well as an upward revision to full-year guidance.

Did Edwards raise its 2026 guidance?

Yes, it raised revenue growth guidance from 7-9% to 8-10%.

What was the EPS for Q2?

EPS was $0.68, beating estimates of $0.65.

Edwards Lifesciences Q2 Earnings Beat Estimates, Stock Rises

Edwards Lifesciences (EW) beat Q2 2026 earnings and revenue estimates, driven by strong TAVR demand and adoption of mitral and tricuspid therapies. The company also raised its full-year guidance.

By: Wrqti Editorial

July 24, 2026

2 min read

Source: Zacks

Key Numbers

revenue

1.65B

eps

0.68

Edwards Lifesciences (NYSE: EW) reported second-quarter 2026 financial results that exceeded analyst expectations on both revenue and earnings, sending shares higher in after-hours trading.

Key Financial Results

Metric	Q2 2026	Estimate	Beat
Revenue	$1.65 billion	$1.60 billion	+3.1%
EPS	$0.68	$0.65	+4.6%

Highlights from the Report

The company attributed the strong performance to robust demand for its TAVR (transcatheter aortic valve replacement) system and increasing adoption of its mitral and tricuspid therapies. Operational efficiencies also contributed to margin improvement.

Forward Guidance

Edwards raised its full-year 2026 revenue guidance to 8-10% growth, up from the prior range of 7-9%.

Market Reaction

Shares of EW rose approximately 3.5% in after-hours trading, reflecting investor optimism over the earnings beat and improved outlook.

What This Means for Investors

The earnings beat underscores the continued momentum in Edwards' structural heart business, driven by expanding TAVR indications and growing adoption of mitral/tricuspid therapies. However, competitive dynamics and pricing pressures remain key factors to watch.

Frequently Asked Questions

Revenue was $1.65 billion, beating estimates of $1.60 billion.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.